These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 5308739)

  • 1. The effect of L-dopa on monoamine metabolites in Parkinson's disease.
    van Woert MH; Bowers MB
    Experientia; 1970; 26(2):161-3. PubMed ID: 5308739
    [No Abstract]   [Full Text] [Related]  

  • 2. Predictive value of the probenecid test for the effect of L-DOPA therapy in Parkinson's disease.
    Lakke JP; Korf J; Van Praag HM; Schut T
    Nat New Biol; 1972 Apr; 236(68):208-9. PubMed ID: 4553111
    [No Abstract]   [Full Text] [Related]  

  • 3. On the relationship between L-DOPA therapy and CSF monoamine metabolites in Parkinson's disease.
    Casati C; Agnoli A; Jori A; Dolfini E
    Z Neurol; 1973 Apr; 204(2):149-54. PubMed ID: 4121468
    [No Abstract]   [Full Text] [Related]  

  • 4. 5-Hydroxyindoleacetic acid in cerebrospinal fluid of patients with Parkinson's syndrome treated with L dopa.
    Johansson B; Roos BE
    Eur J Clin Pharmacol; 1971 Sep; 3(4):232-5. PubMed ID: 5151306
    [No Abstract]   [Full Text] [Related]  

  • 5. Central monoamine metabolism in Parkinson's disease.
    Chase TN; Ng LK
    Arch Neurol; 1972 Dec; 27(6):486-91. PubMed ID: 5083866
    [No Abstract]   [Full Text] [Related]  

  • 6. Amine metabolites in the cerebrospinal fluid in Parkinson's disease and the response to levodopa.
    Gumpert J; Sharpe D; Curzon G
    J Neurol Sci; 1973 May; 19(1):1-12. PubMed ID: 4715017
    [No Abstract]   [Full Text] [Related]  

  • 7. Metabolism of L-dihydroxyphenylalanine by patients with Parkinson's disease.
    Tyce GM; Muenter MD; Owen CA
    Mayo Clin Proc; 1970 Sep; 45(9):645-56. PubMed ID: 5311767
    [No Abstract]   [Full Text] [Related]  

  • 8. Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1973; 9(6):349-62. PubMed ID: 4712542
    [No Abstract]   [Full Text] [Related]  

  • 9. Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease.
    van Woert MH; Bowers MB
    Neurology; 1970 Apr; 20(4):377. PubMed ID: 5534981
    [No Abstract]   [Full Text] [Related]  

  • 10. Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.
    Chase TN
    Neurology; 1970 Dec; 20(12):Suppl:36-40. PubMed ID: 5312403
    [No Abstract]   [Full Text] [Related]  

  • 11. Methyldopahydrazine as an adjunct to L-dopa therapy in parkinsonism.
    Chase TN; Watanabe AM
    Neurology; 1972 Apr; 22(4):384-92. PubMed ID: 5062828
    [No Abstract]   [Full Text] [Related]  

  • 12. Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF.
    Pullar IA; Dowson JH; Ahmed R; Chow R; Gillingham FJ
    Confin Neurol; 1972; 34(1):143-8. PubMed ID: 5084388
    [No Abstract]   [Full Text] [Related]  

  • 13. Catecholamine metabolism during oral administration of levodopa.
    Hinterberger H; Andrews CJ
    Arch Neurol; 1972 Mar; 26(3):245-52. PubMed ID: 5061285
    [No Abstract]   [Full Text] [Related]  

  • 14. Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF.
    Pullar IA; Dowson JH; Ahmed R; Chow R; Gillingham FJ
    Confin Neurol; 1972; 34(2):143-8. PubMed ID: 4666057
    [No Abstract]   [Full Text] [Related]  

  • 15. The balance of biogenic amines as condition for normal behaviour.
    Birkmayer W; Danielczyk W; Neumayer E; Riederer P
    J Neural Transm; 1972; 33(2):163-78. PubMed ID: 4643007
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of Parkinson's disease with amantadine and L-Dopa.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1972; 7(4):228-40. PubMed ID: 4556618
    [No Abstract]   [Full Text] [Related]  

  • 17. Acid monoamine metabolites in the cerebrospinal fluid of patients with Parkinson's disease.
    Rinne UK; Sonninen V
    Neurology; 1972 Jan; 22(1):62-7. PubMed ID: 4550499
    [No Abstract]   [Full Text] [Related]  

  • 18. Parkinson's disease. Modification by 5-hydroxytryptophan.
    Chase TN; Ng LK; Watanabe AM
    Neurology; 1972 May; 22(5):479-84. PubMed ID: 4563493
    [No Abstract]   [Full Text] [Related]  

  • 19. Kantamaneni BD, Curzon G:Comparison of benefit from L-dopa in Parkinsonism with increase of amine metabolites in the CSF.
    Godwin-Austen RB
    J Neurol Neurosurg Psychiatry; 1971 Jun; 34(3):219-23. PubMed ID: 5571307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinsonism-dementia and amyotrophic lateral sclerosis of Guam. Effect of probenecid on monoamine catabolite levels in cerebrospinal fluid.
    Chase RN; Schnur JA; Brody JA; Gordon EK
    Arch Neurol; 1971 Jul; 25(1):9-13. PubMed ID: 5146413
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.